Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069332 | 1.00 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL3076773 | 1.00 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL27892108 | 0.90 | MAPT (0.67) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL9516620 | 0.86 | MAPT (0.82) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL3677980 | 0.86 | MAPT (0.67) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL23080142 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL16975095 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL18241727 | 0.86 | MAPT (0.71) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL6400133 | 0.84 | MAPT (0.69) | MAPTALDH1A1PKMHPGDGPR139 | |
| SCHEMBL31373866 | 0.84 | MAPT (0.69) | MAPTALDH1A1PKMHPGDGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | claimed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | claimed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | claimed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | claimed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | claimed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | claimed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | claimed |
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-08-13 | — | — | US | claimed |
| EP-2260029-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | Sandoz AG (CH) | 2010-12-15 | — | — | EP | claimed |
| WO-2010131025-A1 | SITAGLIPTIN SYNTHESIS | GENERICS [UK] LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010123872-A1 | PLANT GROWTH ENHANCEMENT WITH COMBINATIONS OF PESA AND PLANT GROWTH REGULATORS | VALENT BIOSCIENCES CORPORATION (US) | 2010-10-28 | — | — | WO | claimed |
| WO-2010123849-A1 | FUNGICIDAL COMPOSITION | VALENT BIOSCIENCES CORPORATION (US) | 2010-10-28 | — | — | WO | claimed |
| WO-2010123851-A1 | PLANT GROWTH ENHANCEMENT WITH COMBINATIONS OF PESA AND HERBICIDES | VALENT BIOSCIENCES CORPORATION (US) | 2010-10-28 | — | — | WO | claimed |
| US-20100267557-A1 | Plant Growth Enhancement with Combinations of PESA and Plant Growth Regulators | VALENT BIOSCIENCES LLC | 2010-10-21 | — | — | US | claimed |
| US-20100267556-A1 | Plant Growth Enhancement with Combinations of PESA and Herbicides | VALENT BIOSCIENCES LLC | 2010-10-21 | — | — | US | claimed |
| US-20100267565-A1 | Fungicidal Composition | VALENT BIOSCIENCES LLC | 2010-10-21 | — | — | US | claimed |
| WO-2009122215-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2009-10-08 | — | — | WO | claimed |
| WO-2009106486-A1 | PREPARATION OF MORPHOLINE DERIVATIVES | SANDOZ AG (CH) | 2009-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1035/4885ALDH1A1 1151/4885PKM 2285/4885 |
| US-20100267557-A1 | Plant Growth Enhancement with Combinations of PESA and Plant Growth Regulators | PSAT1, GFM1, PTAR1 | MAPT 3703/4885ALDH1A1 2409/4885PKM 390/4885 |
| US-10377714-B2 | Trans-isomeric heterocyclic compounds and preparation thereof | C1S, FURIN, C5 | MAPT 2716/4885ALDH1A1 880/4885PKM 1719/4885 |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20100267565-A1 | Fungicidal Composition | PSAT1, SUCLG1, HOGA1 | MAPT 391/4885ALDH1A1 1741/4885PKM 268/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | MAPT 1035/4885ALDH1A1 1151/4885PKM 2285/4885 |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | MAPT 1009/4885ALDH1A1 1161/4885PKM 2423/4885 |
| US-20100267556-A1 | Plant Growth Enhancement with Combinations of PESA and Herbicides | PSAT1, GLUL, PAOX | MAPT 2570/4885ALDH1A1 820/4885PKM 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.